Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Cancer Clinical Trial

Official title:

Prospective Phase II Single-arm Study of Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03885219
• Other study ID #: HS-1751
• Status: Recruiting
• Phase: Phase 2
• Start date: May 1, 2019
• Est. completion date: April 2022

Study information

• Verified date: February 2020
• Source: Peking Union Medical College Hospital
• Contact: TaiPing Zhang
• Phone: 13520132976
• Email: Tpingzhang[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a single-arm, multi-center, open-label prospective phase II clinical study designed to evaluate the efficacy and safety of nab-paclitaxel and S-1 in patients with locally advanced pancreatic cancer. A total of 60 subjects who meet the criteria will be treated with nab-paclitaxel and S-1. The primary endpoint is 6 months progression free survival rate, and secondary endpoints include objective response rate, overall survival, progression free survival and toxicities.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: April 2022
• Est. primary completion date: March 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Patients have good compliance, can understand the research process of this study, and sign a written informed consent

2. Patients with pathologically confirmed pancreatic adenocarcinoma.

3. Patients who have not received prior chemotherapy, radiotherapy or other systematic treatment for pancreatic cancer;

4. Patients with locally advanced pancreatic cancer ( NCCN Version 1,2019 criteria).

5. ECOG PS 0-1;

6. Tumor size is measurable according to RECIST1.1 criteria

7. Expected survival over 3 months;

8. Bone marrow function: neutrophils=1.5x109/L, platelets =100x109/L, hemoglobin= 90g/L;

9. Liver and kidney function: serum creatinine=1.5ULT; AST and ALT= 2.5 ULT; total bilirubin = 1.5 ULT;

10. No contraindications to the use of S-1 and nab-paclitaxel.

Exclusion Criteria:

1. = Grade 2 existing peripheral neuropathy;

2. Any other malignancy within 5 years prior to enrollment, with the exception of adequately treated in-situ carcinoma of the cervix, uteri, bladder, or nonmelanomatous skin cancer.

3. Active, uncontrolled infection(s) requiring systemic therapy, defined as ongoing signs/symptoms related to the infection without improvement despite appropriate treatment.

4. Severe, active co-morbidity, defined as follows:

Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months Transmural myocardial infarction within the 6 months of study registration Uncontrolled hypertension, diabetes or arrhythmia. Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization.

5. Not able to take medicine orally.

6. Pregnancy or lactation, and women of childbearing age who refused to take appropriate contraceptive measures during the course of this study;

7. Participation in other clinical trial within 30 days before the first dose of the drug;

Related Conditions & MeSH terms

• Locally Advanced Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• Nab-paclitaxel and S-1
Nab-paclitaxel: 120 mg/m2 d1, 8, S-1:Body surface area < 1.25 m2, 80 mg/d; Body surface area = 1.25 m2 , < 1.5 m2, 100 mg/d; Body surface area =1.5 m2, 120 mg/d; Bid, d1-14; repeat every 21 days.

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	6-month progression-free survival (PFS)	The proportion of patients who did not experience disease progression or die from disease progression within 6 months from the registration.	6 months
Secondary	Objective Response Rate (ORR)	Refers to the proportion of patients with partial tumor remission (PR) and complete remission (CR).	From date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.